Rgia A Othman1, Semone B Myrie1, David Mymin2, Louise S Merkens3, Jean-Baptiste Roullet3, Robert D Steiner4, Peter J H Jones5. 1. Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; Richardson Center for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada. 2. Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. 3. Pediatrics, Institute on Development and Disability/Doernbecher Children's Hospital, Oregon Health and Science University, Portland, OR. 4. Pediatrics, Institute on Development and Disability/Doernbecher Children's Hospital, Oregon Health and Science University, Portland, OR; Molecular and Medical Genetics, Institute on Development and Disability/Doernbecher Children's Hospital, Oregon Health and Science University, Portland, OR; Marshfield Clinic Research Foundation, Marshfield, WI and the University of Wisconsin, Madison, WI. 5. Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; Richardson Center for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada. Electronic address: peter_jones@umanitoba.ca.
Abstract
OBJECTIVE: To assess if ezetimibe (EZE), a sterol-absorption inhibitor, improves platelet (PLT) count and size relative to its effect on plasma plant sterol (PS) in patients with sitosterolemia (STSL). STUDY DESIGN: Patients with STSL (5 males, 3 females, 16-56 years of age) receiving EZE intervention as part of their routine care participated in this study. EZE was discontinued for 14 weeks (off) and then resumed for another 14 weeks (on). Hematology variables along with plasma and red blood cells (RBC) PS and total cholesterol (TC) levels were measured at the end of each phase. RESULTS: EZE increased PLT count (23% ± 9%) and decreased mean PLT volume (MPV; 10% ± 3%, all P < .05). In patients off EZE, PLT counts inversely correlated (r = -0.96 and r = -0.91, all P < .01) with plasma and RBC PS to TC ratio (PS/TC), and MPV positively correlated (r = 0.91, P = .03 and r = 0.93, P = .02) with plasma and RBC PS/TC. EZE reduced plasma and RBC sitosterol (-35% ± 4% and -28% ± 3%), total PS (-37% ± 4% and -28% ± 3%, all P < .0001) levels, and PS/TC (-27% ± 4% and -28% ± 4%, P < .01). CONCLUSIONS: EZE reduces plasma and RBC PS levels, while increasing PLT count and decreasing MPV, and thereby may reduce the risk for bleeding in STSL. Plasma PS levels and ABCG5/ABCG8 genes should be analyzed in patients with unexplained hematologic abnormalities.
OBJECTIVE: To assess if ezetimibe (EZE), a sterol-absorption inhibitor, improves platelet (PLT) count and size relative to its effect on plasma plant sterol (PS) in patients with sitosterolemia (STSL). STUDY DESIGN:Patients with STSL (5 males, 3 females, 16-56 years of age) receiving EZE intervention as part of their routine care participated in this study. EZE was discontinued for 14 weeks (off) and then resumed for another 14 weeks (on). Hematology variables along with plasma and red blood cells (RBC) PS and total cholesterol (TC) levels were measured at the end of each phase. RESULTS: EZE increased PLT count (23% ± 9%) and decreased mean PLT volume (MPV; 10% ± 3%, all P < .05). In patients off EZE, PLT counts inversely correlated (r = -0.96 and r = -0.91, all P < .01) with plasma and RBC PS to TC ratio (PS/TC), and MPV positively correlated (r = 0.91, P = .03 and r = 0.93, P = .02) with plasma and RBC PS/TC. EZE reduced plasma and RBC sitosterol (-35% ± 4% and -28% ± 3%), total PS (-37% ± 4% and -28% ± 3%, all P < .0001) levels, and PS/TC (-27% ± 4% and -28% ± 4%, P < .01). CONCLUSIONS: EZE reduces plasma and RBC PS levels, while increasing PLT count and decreasing MPV, and thereby may reduce the risk for bleeding in STSL. Plasma PS levels and ABCG5/ABCG8 genes should be analyzed in patients with unexplained hematologic abnormalities.
Authors: K E Berge; H Tian; G A Graf; L Yu; N V Grishin; J Schultz; P Kwiterovich; B Shan; R Barnes; H H Hobbs Journal: Science Date: 2000-12-01 Impact factor: 47.728
Authors: R H Knopp; H Gitter; T Truitt; H Bays; C V Manion; L J Lipka; A P LeBeaut; R Suresh; B Yang; E P Veltri Journal: Eur Heart J Date: 2003-04 Impact factor: 29.983
Authors: D Lütjohann; K von Bergmann; W Sirah; G Macdonell; A O Johnson-Levonas; A Shah; J Lin; A Sapre; T Musliner Journal: Int J Clin Pract Date: 2008-10 Impact factor: 2.503
Authors: Don S Lin; Robert D Steiner; Louise S Merkens; Anuradha S Pappu; William E Connor Journal: Atherosclerosis Date: 2009-07-23 Impact factor: 5.162
Authors: Peter J H Jones; Maryam Shamloo; Dylan S MacKay; Todd C Rideout; Semone B Myrie; Jogchum Plat; Jean-Baptiste Roullet; David J Baer; Kara L Calkins; Harry R Davis; P Barton Duell; Henry Ginsberg; Helena Gylling; David Jenkins; Dieter Lütjohann; Mohammad Moghadasian; Robert A Moreau; David Mymin; Richard E Ostlund; Rouyanne T Ras; Javier Ochoa Reparaz; Elke A Trautwein; Stephen Turley; Tim Vanmierlo; Oliver Weingärtner Journal: Nutr Rev Date: 2018-10-01 Impact factor: 7.110
Authors: Rgia A Othman; Semone B Myrie; David Mymin; Jean-Baptiste Roullet; Robert D Steiner; Peter J H Jones Journal: Atherosclerosis Date: 2017-03-10 Impact factor: 5.162
Authors: Rgia A Othman; Semone B Myrie; David Mymin; Jean-Baptiste Roullet; Andrea E DeBarber; Robert D Steiner; Peter J H Jones Journal: J Pediatr Date: 2017-06-16 Impact factor: 4.406